RNTX

In November 2025, the FDA lifted a clinical hold on the Phase 2 RENEW trial of LTI-03, increasing the stock price, but a subsequent publication led to a slight decline. In January 2026, Orphan Drug Designation from the European Medicines Agency for LTI-03 resulted in a minor stock price decrease. In March 2026, dosing the first patient in the Phase 2 trial of LTI-03 for IPF led to a stock price decrease. In April 2026, a clinical trial update for the Phase 2 RENEW study of LTI-03 was followed by a stock price decline. On April 30, 2026, the pricing of a $50 million public offering at $1.00 per share resulted in a significant stock price drop. Shareholder dilution has been a major risk, with total shares outstanding growing significantly.